Champions Oncology Q3 revenue dips 3%

Champions Oncology

12/03/2026 20:29

Overview

US oncology research firm's fiscal Q3 revenue fell 3% due to absence of data license revenue recognized yr ago

Study service revenue hit record, up 32% yr/yr on strong study execution and backlog conversion

Outlook

Champions Oncology expects year-over-year revenue growth for the fiscal year

Company anticipates positive adjusted EBITDA for the full fiscal year

Result Drivers

BACKLOG CONVERSION - Co said Q3 study service revenue rose as previously booked work was completed and recognized

ABSENCE OF DATA LICENSE REVENUE - Total revenue declined yr/yr due to lack of $4.5 mln data license transaction recognized in prior-year period

Company press release: ID:nACSZSZC0a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$16.60 mln
Q3 Adjusted EPS
$0.04
Q3 EPS
-$0.02


Analyst Coverage

The stock recently traded at 57 times the next 12-month earnings vs. a P/E of 36 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)